Icosapent ethyl: Where will it fit into guideline-based medical therapy for high risk atherosclerotic cardiovascular disease?

Overview of attention for article published in Trends in Cardiovascular Medicine, May 2019

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (88th percentile)
Above-average Attention Score compared to outputs of the same age and source (52nd percentile)

Mentioned by

twitter: 24 X users

facebook: 1 Facebook page

Readers on

mendeley: 52 Mendeley

So far, Altmetric has seen 30 X posts from 24 X users, with an upper bound of 115,425 followers.

RT @SABOURETCardio: Icosapent ethyl: Where will it fit into guideline-based medical therapy for high risk atherosclerotic cardiovascular di…

RT @JohnCappello: Icosapent Ethyl: Where will it fit into guideline-based medical therapy for high risk atherosclerotic cardiovascular dise…

RT @SABOURETCardio: Icosapent ethyl: Where will it fit into guideline-based medical therapy for high risk atherosclerotic cardiovascular di…

RT @TerraPharma1: #vascepa #icosapentethyl $AMRN https://t.co/q7eKLi1MWA

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 26 additional X posts.

Login to access the Sentiment Analysis related to this output.